Compare CORT & HMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CORT | HMY |
|---|---|---|
| Founded | 1998 | 1950 |
| Country | United States | South Africa |
| Employees | N/A | 34350 |
| Industry | Biotechnology: Pharmaceutical Preparations | Precious Metals |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.7B | 9.8B |
| IPO Year | 2001 | N/A |
| Metric | CORT | HMY |
|---|---|---|
| Price | $91.79 | $14.43 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 2 |
| Target Price | ★ $96.50 | $16.00 |
| AVG Volume (30 Days) | 986.3K | ★ 3.2M |
| Earning Date | 04-30-2026 | 02-04-2016 |
| Dividend Yield | N/A | ★ 2.13% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $761,407,000.00 | N/A |
| Revenue This Year | $26.08 | $37.43 |
| Revenue Next Year | $26.98 | $27.44 |
| P/E Ratio | ★ N/A | $15.60 |
| Revenue Growth | ★ 12.79 | N/A |
| 52 Week Low | $28.66 | $13.03 |
| 52 Week High | $95.11 | $26.04 |
| Indicator | CORT | HMY |
|---|---|---|
| Relative Strength Index (RSI) | 64.92 | 40.37 |
| Support Level | $76.41 | $14.32 |
| Resistance Level | $95.11 | $18.30 |
| Average True Range (ATR) | 3.83 | 0.51 |
| MACD | -0.92 | -0.04 |
| Stochastic Oscillator | 65.40 | 8.64 |
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.
Harmony Gold Mining Co Ltd is engaged in gold mining and related activities, including exploration, extraction, and processing. The group's primary product is gold bullion, produced at operations in South Africa and Papua New Guinea. Gold byproducts include uranium and silver. Strategic projects such as the Wafi-Golpu Project in the New Guinea Mobile Belt, the Eva Copper Project in the Mt Isa Inlier, Queensland, Australia, and the MAC Copper acquisition position the company as a gold-copper producer. The company operates across South Africa, Papua New Guinea, and Australia.